Steven Hall

Royal Society Newton International Fellow

Steve completed his BSc with First Class Honours in 2011 at Mount Allison University, a small school in New Brunswick, Canada. He then moved to Halifax, Nova Scotia, where he obtained his PhD in Pharmacology from Dalhousie University in 2017. He received a Mitacs Elevate Fellowship for his first postdoctoral fellowship (2017-2019), which he completed in collaboration with a local nutraceutics company in Halifax along with Dalhousie's College of Pharmacy. In February of 2020, after receiving a Newton International Fellowship through the Royal Society, he moved across the Atlantic to join the Centre for Snakebite Research and Interventions. 


The discovery and study of small molecule therapeutics as treatments for snakebite-induced local tissue damage, such as necrosis. 

Selected publications

  • Hall SR, Reid AJ, Eng J, McKeown BT, St-Onge M, Goralski KB. A lipid-based oral supplement protects skin cells in culture from ultraviolet light via antioxidant and anti-inflammatory mechanisms: Photoprotective properties of an oral natural health product. Journal of Natural Health Product Research, 2020.

    Hall SR, Goralski KB. ZATT, TDP2, and SUMO2: Breaking the tie that binds TOP2 to DNA. Translational Cancer Research, 2018, 7:1-6, DOI: 10.21037/tcr.2018.02.03.

    Hall SR, Toulany J, Bennett LG, Martinez-Farina CF, Robertson AW, Jakeman DL, Goralski KB. Jadomycins inhibit type II topoisomerases and promote DNA damage and apoptosis in multidrug resistant triple negative breast cancer cells. Journal of Pharmacology and Experimental Therapeutics, 2017, 363(2):196-210, jpet.117.241125; DOI:

    Hall SR, Blundon HL, Ladda MA, Robertson AW, Martinez-Farina CF, Jakeman DL, Goralski KB. Jadomycin breast cancer cytotoxicity is mediated by a copper-dependent, reactive oxygen species-inducing mechanism. Pharmacology Research & Perspectives, 2015, 3(2), e00110, DOI: 10.1002/prp2.110.

    Issa ME, Hall SR, Dupuis SN, Graham CL, Jakeman DL, Goralski KB. Jadomycins are Cytotoxic to ABCB1-, ABCC1- and ABCG2-Overexpressing MCF7 Breast Cancer Cells. Anti-Cancer Drugs, 2014, 25(3), 255-69, DOI: 10.1097/CAD.0000000000000043.

    Hall SR, Roy R, McLaughlin DT, Sullivan KJ, Barclay LRC, Vogels CM, Decken A, and Westcott SA. The Synthesis and Molecular Structure of 1-(3,4-Dihydroxyphenethyl)-3-hydroxy-2-methylpyridin-4(1H)-one Hydrochloride Methanol Solvate. Crystals, 2013, 3(2), 333-38, DOI: 10.3390/cryst3020333.